Spinal Cord Injury-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Publisher Name :
Date: 01-Nov-2016
No. of pages: 100
This report is available at upto 40% Discount. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's Report, "Spinal Cord Injury-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Spinal Cord Injury Report is to understand the market and pipeline status of the drugs around the Spinal Cord Injury to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight's Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Spinal Cord Injury. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight's report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Scope:

- A snapshot of the global Market and Phase III therapeutics scenario for Spinal Cord Injury.

- A review of the marketed products under prescription for Spinal Cord Injury, regulatory information and marketing status.

- Coverage of global patent coverage and detailed commentaries on the US patent challenges.

- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

- Product profiles for marketed products for Spinal Cord Injury with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

- Coverage of API Manufacturers for Spinal Cord Injury drugs in the United States, Europe and Asian Regions with location details.

- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Spinal Cord Injury drugs.

- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Spinal Cord Injury drugs.

- Coverage of Spinal Cord Injury Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

- Key discontinued Marketed products.

- Global Sales Figure to 2018.

Reasons to buy

- Evaluate the marketing status and exclusivity details of Spinal Cord Injury key products to exploit opportunities for generic drug development opportunities.

- Identify and understand important and diverse types of therapeutics under Phase III development for Spinal Cord Injury.

- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Spinal Cord Injury.

- API intelligence over marketed drugs for Spinal Cord Injury and gaining primary intelligence over active ingredients manufacturers across the globe.

- API intelligence over leading Phase III Pipeline drugs.

- Develop and design strategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

- Understanding the scope of the Phase III Drugs with nil regulatory filings.

- Understanding the chemical route of synthesis of approved drugs for Spinal Cord Injury.

- Uncovering opportunities in the rapidly growing US market.

Spinal Cord Injury-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Table of Contents

1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Spinal Cord Injury
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Spinal Cord Injury
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Spinal Cord Injury
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

Spinal Cord Injury Therapeutic Market, US, Marketed Drugs by Application Type, 2016
Spinal Cord Injury Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
Spinal Cord Injury Therapeutic Market, US, (Year), 2016
Spinal Cord Injury Marketed Drugs, API Manufacturers by US DMF Status, 2016
Spinal Cord Injury Marketed Drugs, US DMF Status Drug Specific (Number), 2016
Spinal Cord Injury Drugs, API Manufacturers, Europe by Country, 2016
Spinal Cord Injury Drugs, API Manufacturers, India by State, 2016
Spinal Cord Injury Drugs, API Manufacturers, China by Province, 2016
Spinal Cord Injury Drugs, API Manufacturers by Geography 2016
Spinal Cord Injury Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
Spinal Cord Injury Therapeutic Market, Global Sales-2018 (in million USD)
API Manufacturers for Drug, 2016
Phase III Drugs for Spinal Cord Injury, 2016
Discontinued Drugs for Spinal Cord Injury, 2016

List of Figures

Spinal Cord Injury Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
Spinal Cord Injury Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
Spinal Cord Injury Therapeutic Market, US, (Year), 2016
Spinal Cord Injury Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
Spinal Cord Injury Marketed Drugs, US DMF Status Drug Specific (Number), 2016
Spinal Cord Injury Drugs, API Manufacturers, Europe by Country, 2016
Spinal Cord Injury Drugs, API Manufacturers, India by State, 2016
Spinal Cord Injury Drugs, API Manufacturers, China by Province, 2016
Spinal Cord Injury Drugs, API Manufacturers by Geography 2016
Spinal Cord Injury Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
Spinal Cord Injury Therapeutic Market, Global Sales 2018 (in million USD)
Drug, Patent/Exclusivity Expiry (Year), 2016
  • Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 509
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their co......
  • Spinal Cord Injury - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 192
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2016, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and s......
  • Herpes Simplex Encephalitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Herpes Simplex Encephalitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Herpes Simplex Encephalitis Report is to understand the market and pipeline status of the drugs around the Herpes Simplex Encephalitis to explore the generic development opportunities, licensing opportunities a......
  • Acute Spinal Cord Injury-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Acute Spinal Cord Injury-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Acute Spinal Cord Injury. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collabora......
  • Meningitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Meningitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Meningitis Report is to understand the market and pipeline status of the drugs around the Meningitis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipel......
  • Meningitis-API Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Bacterial (Pyogenic) Meningitis-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Bacterial (Pyogenic) Meningitis-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Bacterial (Pyogenic) Meningitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licens......
  • Global Spinal Cord Partnering 2010 to 2016
    Published: 01-Nov-2016        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understandi......
  • Global Neuropathy Partnering 2010 to 2016
    Published: 01-Nov-2016        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understandi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs